What happened
Inito secured $29 million in funding to develop AI-engineered antibodies, expanding its at-home health testing capabilities. This initiative aims to enhance the precision of current fertility tests and facilitate new diagnostic offerings by leveraging artificial intelligence. The company's strategic investment in AI underscores a commitment to innovation within the femtech sector, providing more accurate and personalised insights into fertility.
Why it matters
The introduction of AI-engineered antibodies for at-home fertility testing raises due diligence requirements for data handling and interpretation within the femtech sector. This increases exposure for compliance and product development teams to the complexities of AI-driven diagnostic outputs and the associated data privacy implications, particularly concerning sensitive health information. It also introduces an oversight burden for ensuring the validation and reliability of AI-enhanced diagnostic precision.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
